In a prior study showing efficacy of STING agonists against murine syngeneic AML models, it was speculated that, in addition to the benefits of IFN produced by host cells, therapeutic benefit might also depend on conditioning of tumor vasculature by augmented levels of TNFα (24). The gene discussed is STING1; the disease is neoplasm.